Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 106

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 106
---
 the fiscal year ended March 31, 2024). The increase was primarily due to a tax expense reduction of JPY 63.5 billion recorded during the fiscal year ended March 31, 2024 resulting from the reversal of the income taxes payable in excess of the settlement with Irish Revenue Commissioners with respect to a tax assessment related to the treatment of an acquisition break fee Shire received from AbbVie in 2014 and an increase in tax expenses due to the reassessment of recoverability of deferred tax assets as well as higher pretax earnings during the fiscal year ended March 31, 2025.

Net Profit for the Year

As a result of the above factors, Net Profit for the Year wasJPY 108.1 billion(JPY -36.1 billion and -25.0% AER,-33.1% CER) and Net Profit for the Year attributable to owners of the Company wasJPY 107.9 billion( JPY -36.1 billion and -25.1% AER, -33.2% CER).

Table of Contents

Fiscal Year Ended March 31, 2024 compared with the Fiscal Year Ended March 31, 2023

Revenue

Revenue for the fiscal year ended March 31, 2024 was JPY 4,263.8 billion (JPY +236.3 billion and +5.9% AER, +1.5% CER). The increase was primarily attributable to favorable foreign exchange rates and growth from business momentum of Plasma-Derived Therapies (“ PDT”) Immunology, Gastroenterology (“ GI”), Rare Diseases and Oncology. The increase in these business areas was offset by the decrease in Neuroscience. Revenue outside of these key business areas decreased mainly due to the decline in sales of AZILVA (for hypertension), which were JPY 33.6 billion (JPY -39.3 billion and -53.9% AER, -53.9% CER) and impacted by generic entrants in Japan, as well as the lower revenue contribution from COVID-19 vaccines in Japan.

Revenue by Geographic Region

The following shows revenue by geographic region:

                                      Billion JPY or percentage                                                                           
                                      For the fiscal year ended                                              AER                     CER  
                                      March 31,                                                                                           
  Revenue:                                                                                                                                
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Japan                               ¥                                512.0